You are here

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

TitleEfficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
Publication TypeJournal Article
Year of Publication2012
AuthorsDejesus E, Rockstroh JK, Lennox JL, Saag MS, Lazzarin A, Zhao J, Wan H, Rodgers AJ, Walker ML, Miller M, Dinubile MJ, Nguyen B-, Teppler H, Leavitt R, Sklar P
Corporate AuthorsSTARTMRK Investigators
JournalHIV Clin Trials
Volume13
Issue4
Pagination228-32
Date Published2012 Jul-Aug
ISSN1528-4336
KeywordsAcquired Immunodeficiency Syndrome, Adenine, Adolescent, Adult, Aged, Anti-HIV Agents, Benzoxazines, CD4 Lymphocyte Count, Deoxycytidine, Drug Resistance, Viral, Drug Therapy, Combination, Emtricitabine, Female, HIV-1, Humans, Male, Middle Aged, Organophosphonates, Pyrrolidinones, Raltegravir Potassium, Tenofovir
Abstract

We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.

DOI10.1310/hct1304-228
Alternate JournalHIV Clin Trials
PubMed ID22849964